The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets
By B. Allard, M. Longhi, Simon C. Robson, J. Stagg. Immunological Reviews, 2017
839 citations recorded by the source corpus.
Cancers are able to grow by subverting immune suppressive pathways, to prevent the malignant cells as being recognized as dangerous or foreign. This mechanism prevents the cancer from being eliminated by the immune system and allows disease to progress from a very early stage to a lethal state. Immunotherapies are newly developing interventions that modify the patient's immune system to fight cancer, by either directly stimulating rejection‐type processes or blocking suppressive pathways. Extracellular adenosine generated by the ectonucleotidases CD39 and CD73 is a newly recognized “immune checkpoint mediator” that interferes with anti‐tumor immune responses. In this review, we focus on CD39 and CD73 ectoenzymes and encompass aspects of the biochemistry of these molecules as well as detailing the distribution and function on immune cells. Effects of CD39 and CD73 inhibition in preclinical and clinical studies are discussed. Finally, we provide insights into potential clinical application of adenosinergic and other purinergic‐targeting therapies and forecast how these might develop in combination with other anti‐cancer modalities.
Subfields: Materials Chemistry, Oncology, Physiology
View Paper: https://www.semanticscholar.org/paper/3f8c868be5e19e8f79cb75bf3117a77bb9121914
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Physiology
Citations in the corpus
- Understanding the Holobiont: How microbial metabolites affect human health and shape the immune system (2017, background): “ENTPD1 converts ATP to AMP, which is then quickly metabolized to the anti-inflammatory adenosine by 50-nucleotidase (also known as CD73) (Allard et al., 2017).”